Properties | Information | |
---|---|---|
PhytoCAT-ID | PhytoCAT-1150 | |
Phytochemical name or plant extracts | Rh2 | |
PMID | 15389289 | |
Literature evidence | In the present study, we tested Rh2 on many tumor-cell lines for its effects on cell proliferation, induction of apoptosis, and potential interaction with conventional chemotherapy agents. | |
IUPAC name | NA | |
Phytochemicals’ class or type of plant extracts | Ginsenoside | |
Source of phytochemicals or plant Extracts | Panax ginseng | |
Geographical availability | Khabarovsk, Korea, Manchuria, Primorye | |
Plant parts | Root | |
Other cancers | Breast cancer | |
Target gene or protein | Cyclin D3, CIP1, RNF217, RNA STXBP5-AS1 | |
Gene or Protein evidence | G-Rh2 treatment down-regulated the protein level of cyclin D3 but upregulated the expression of cyclin-dependent kinase (Cdk) inhibitor p21WAF1/CIP1. Screening the target genes of miR-4425 and Rh2 revealed that Rh2, STXBP5-AS1, and miR-4425 consistently regulated tumor suppressor RNF217 at both the RNA and protein level. Ginsenoside Rh2 upregulates long noncoding RNA STXBP5-AS1 to sponge microRNA-4425 in suppressing breast cancer cell proliferation. | |
Target pathways | Notably, up-regulation of STXBP5- AS1 was also observed in Rg3-treated MCF-7 cells, implicating Rh2 and Rg3 as common regulators of the STXBP5-AS1/miR-4425 pathway. Therefore, Rh2 controls the STXBP5-AS1/miR-4425/RNF217 axis to suppress breast cancer cell growth. | |
IC50 | NA | |
Potency | These results suggest that Rh2 possesses strong tumor-inhibiting properties, and potentially can be used in treatments for multidrug-resistant cancers, especially when it is used in combination with conventional chemotherapy agents. | |
Cell line/ mice model | MCF-7 | |
Additional information | The ginsenoside Rh2 has strong anti-cancer, anti-inflammatory, and anti-diabetic effects. | |
PubChem ID | NA | |
Additional PMIDs | 10200336 34764730 | |
Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:91472-1 | |
Safety | NA |